Primary aldosteronism (PA) is a common cause of arterial hypertension: in the PA
Prevalence in Hypertensives (PAPY) Study, the prevalence of PA was 11.2% in consecutive …

Primary aldosteronism (PA), a common, albeit markedly underdiagnosed cause of curable
arterial hypertension, is characterized by plasma levels of aldosterone that are inappropriate …

In 1953, Lipicki published in Polish the first report of a case of arterial hypertension and
hypokalemia caused by an adrenocortical adenoma, which remained unnoticed until …

Primary aldosteronism (PA) is the most common secondary form of arterial hypertension,
with a particularly high prevalence among patients with resistant hypertension. Aldosterone …

Several studies over the past 3 decades document a higher prevalence of primary
aldosteronism (PA) among hypertensive patients than generally presumed. PA exists as a …

After discussing in Part I (Rossi et al, J Nephrol. 2008; 21: 447-454) the screening strategy to
identify the hypertensive patients with primary aldosteronism (PA), we report here an update …

Primary aldosteronism (PA) is the most common etiology of endocrine hypertension (HTN),
and recent prevalence studies suggest that it may be under-diagnosed. Indications for …

Primary aldosteronism (PA) has a prevalence in the general hypertensive population from 5
to 10%, and is widely recognized as the most frequent form of secondary hypertension. The …

Arterial hypertension is a major risk factor for cardiovascular disease. The prevalence of
primary aldosteronism (PA) ranges from 5% to 10% in the general hypertensive population …

The Japan Endocrine Society (JES) attempted to develop guidelines for the diagnosis and
treatment of primary aldosteronism (PA). The Task Force Committee (TFC) was composed of …